logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Inspiring News from a Small Firm

Following the news announcing that  Amgen’s (AMGN)  drug KYPROLIS ®  (carfilzomib) extended the lives of patients with relapsed or refractory multiple myeloma in combination with lenalidomide + dexamethasone, we got news from a small company called  Karyopharm Therapeutics (KPTI)  announcing...

Read More

May 2, 2018

0

Amgen Has More Good News. What Is Going on with the CRISPR Gene Editing Firms?

A couple of days following the news that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on  Amgen’s (AMGN)  product  Prolia ®  (denosumab)  for the treatment of  bone loss associated with...

Read More

May 1, 2018

0

Nektar and Takeda Explore Immunotherapy Combinations for Multiple Cancers. Sangamo Is Financing Through Public Offering

NEKTAR Nektar Therapeutics (NKTR) and Takeda Pharmaceutical (TKPYY)   are collaborating to evaluate Nektar’s investigational medicine,  NKTR-214 , with Takeda’s investigational medicine,  TAK-659 ,  as a potential combination for multiple cancer settings.  NKTR-214  is an experimental immuno-stimulatory recognized to  expand specific cancer-fighting T cells...

Read More

April 26, 2018

0

Cures for Hemophilia A and B? See Also: Why EXEL Was a Loser Yesterday

SPARK THERAPEUTICS, SANGAMO THERAPEUTICS AND SALK INSTITUTE CURING HEMOPHILIA?   Hemophilia is an inherited bleeding disorder that causes abnormal or exaggerated bleeding and poor blood clotting. Hemophilia A and Hemophilia B are inherited in an X-linked recessive genetic pattern, so...

Read More

May 11, 2018

0

Excellent news about little known products and Nektar Therapeutics

The Week in Review , which we will post soon, is going to provide news that cancer patients, their parents, their oncologists and investors are anxiously waiting to hear.   The news is about studies with products demonstrating huge improvements...

Read More

November 12, 2018

0

News from PTC Therapeutics, Celgene and Heron Therapeutics

IN THE NEWS PTC THERAPEUTICS   PTC Therapeutics (PTCT)  stock, which dipped yesterday, probably on news announcing a public offering of 4,000,000 shares of its common stock at a public offering price of $27.04 per share. Yesterday, in a crazy market that...

Read More

March 29, 2018

0

A great day for Exelixis

This is just to inform that Europe has approved Cabometyx ®  (cabozantinib) tablets as a monotherapy for hepatocellular carcinoma (HCC) . As you know, Cabometyx belongs to Exelixis (EXEL) . Today Exelixis announced that its partner,  Ipsen,  received approval of...

Read More

November 15, 2018

0

RegenxBio attracts more companies. Why Loxo is important to observe today

We hope you all took advantage of the Thanksgiving holiday to rest and relax. We did. In Today’s NEWS RegenxBio Offers Rocket Pharmaceuticals exclusive, worldwide, rights to adenoviral vector NAV AAV9 for the development of treatments for Danon Disease RegenxBio (RGNX)...

Read More

November 26, 2018

0

Why Celyad stock lost today instead of gaining on good news

Celyad (CYAD) is still a clinical-stage biopharmaceutical company developing advanced or improved CAR-T cell-based therapies. Today, Celyad announced that the first patient has received an injection in Phase 1 of the  alloSHRINK clinical trial,  evaluating its non-gene edited allogeneic CAR-T...

Read More

November 30, 2018

0

CAR-T Immunotherapy Improvement. A Novel Approach and the Firm Behind It

CANCER IMMUNOTHERAPY 2 Nonstop Improvements and Nonstop Discoveries In CAR-T Immunotherapy As we said in the article about checkpoint inhibition as cancer immunotherapy, the approaches that aim at enabling the immune system to fight cancer cells were created to stay...

Read More

April 10, 2017

0

  • Previous
  • 1
  • 2
  • ...
  • 48
  • 49
  • 50
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy